Stem cell transplantation (SCT) is increasingly being used for treatme
nt of chronic lymphocytic leukemia (CLL). The present article summariz
es available clinical results and discusses important aspects of SCT i
n patients with CLL including the preferable type of SCT (allogeneic v
s autologous), timing of SCT, high-dose regimens, purging, and molecul
ar monitoring of residual disease.